Synovial Sarcoma Epidemiology Summary

• According to DelveInsight’s estimates, in 2025, Synovial Sarcoma cases were distributed across the 7MM, with the highest share observed in the United States, followed by the EU4 & UK, while Japan accounted for a comparatively smaller proportion of cases.
• Synovial Sarcoma is more common in developed countries due to the high burden of diagnosed soft tissue sarcomas, greater access to specialized diagnostic services, increased use of molecular testing, and more comprehensive cancer surveillance systems.
• Males face a higher lifetime risk of developing Synovial Sarcoma and experience a greater disease burden compared to females. This disparity is largely attributed to the higher incidence of the disease among males, coupled with demographic and biological factors that contribute to increased prevalence and healthcare burden in this population.
• Synovial Sarcoma is a relatively rare malignancy representing a soft tissue sarcoma (STS) of uncertain differentiation. It accounts for 5–10% of all STS.
• It primarily affects younger individuals, with one-third of patients diagnosed before the age of 30.
• The persistent unmet need in advanced and metastatic synovial sarcoma, along with improved diagnostics and growing adoption of precision oncology, is expected to sustain market growth over the next decade. Expanding access to specialized care, increasing use of biomarker-driven therapies, and the development of targeted and TCR-based cell therapies will continue to drive future market expansion.

Synovial Sarcoma Epidemiology Forecast in the 7MM

• 2025 Incident Cases of Synovial Sarcoma: ~XXXX million
• 2036 Projected Incident Cases of Synovial Sarcoma: ~XXXX million
• Synovial Sarcoma Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Synovial Sarcoma Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Synovial Sarcoma, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Synovial Sarcoma Understanding and Diagnosis Algorithm

Synovial Sarcoma Overview

Synovial sarcoma is a rare, aggressive soft tissue sarcoma characterized by a chromosomal translocation involving the SS18 (SYT) gene, which leads to oncogenic fusion proteins driving tumor development. Despite its name, it does not arise from synovial tissue but most commonly occurs in the deep soft tissues near joints, tendons, and bursae, especially in the extremities. It typically affects adolescents and young adults, though it can occur at any age, and often presents as a deep-seated mass with a high risk of metastasis, most commonly to the lungs. Disease behavior and prognosis depend on factors such as tumor size, location, histologic subtype, metastatic status, and response to multimodal treatment, including surgery, radiotherapy, and systemic therapy.

Synovial Sarcoma Diagnosis

Synovial sarcoma is diagnosed using a combination of clinical assessment, imaging, histopathology, and molecular testing. MRI is used to evaluate tumor size and local extent, while a biopsy provides definitive histological confirmation. The diagnosis is further supported by identifying the characteristic SS18::SSX gene fusion using techniques such as FISH, RT-PCR, or next-generation sequencing, which also aid in treatment planning.

Note: Further details are provided in the report...

Synovial Sarcoma Epidemiology

Key Findings from Synovial Sarcoma Epidemiological Analysis and Forecast

• The total number of incident Synovial Sarcoma cases across the 7MM is expected to increase over 2022–2036, driven by improved diagnostics, greater awareness of rare soft tissue sarcomas, wider use of molecular testing, and improved survival from multidisciplinary care.
• Among the 7MM, the United States has the highest incidence of Synovial Sarcoma in 2025, and these cases are expected to increase during the forecast period.
• Among the EU-4 & UK, Germany reported the highest incidence of Synovial Sarcoma. Spain was found to have the fewest cases in 2025 among all European countries.
• According to DelveInsight estimates, Stage II Synovial Sarcoma accounts for the highest incidence in Japan in 2025, with cases expected to rise over the forecast period.
• The male predominance and earlier onset of Synovial Sarcoma underscore the need for early diagnosis, prompt referral to specialized sarcoma centers, and age- and risk-adapted treatment strategies to improve long-term outcomes.

Access DelveInsight's Synovial Sarcoma Market Insight, Epidemiology and Market Forecast – 2036 to evaluate market trends, emerging therapies, and growth opportunities.

Scope of the Synovial Sarcoma Epidemiology Report

• The report covers a segment of an executive summary, a descriptive overview of Synovial Sarcoma, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Synovial Sarcoma Epidemiology Report Insights

• Synovial Sarcoma Patient Population Forecast

Synovial Sarcoma Epidemiology Report Key Strengths

• Synovial Sarcoma Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Synovial Sarcoma Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Synovial Sarcoma? What will be the growth opportunities across the 7MM concerning the patient population with Synovial Sarcoma?
• What is the historical and forecasted Synovial Sarcoma patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy Synovial Sarcoma Epidemiology

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.